Lupin Pharmaceuticals is recalling 43,860 bottles of Moxifloxacin Ophthalmic Solution USP, 0.5% (3 mL), a prescription antibiotic eye drop used to treat bacterial infections. The recall was initiated because long-term stability testing showed the product did not meet purity and degradation specifications at the three-month mark. This means the medication may contain higher levels of impurities than allowed by safety standards. Consumers should contact their healthcare provider or pharmacist regarding the continued use of this product and return any remaining medication to their pharmacy.
The presence of impurities or degradation products beyond specified limits can reduce the effectiveness of the antibiotic treatment or potentially cause unexpected irritation or adverse reactions in the eye.
Drug Recall Remedy
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.